Purpose Saponins are amphiphilic glycosides found in plants. They have long been used in traditional Asian remedies for their anti-inflammatory, protective, and rejuvenating properties. One representative, Glucuronyl Glucosyloleanolate (GGO), was recently discovered using a combination of artificial intelligence and experimental testing as a depigmenting agent. Its safety has been verified in humans during a patch test on 12 volunteers, followed by an HRIPT study on 100 volunteers. Finally, its depigmenting efficacy has been demonstrated after a clinical trial on 60 volunteers.Methods A 48-h patch test was conducted on 12 volunteers using the pure compound. HRIPT: a patch with 0.1% GGO in mineral oil was applied to 100 volunteers repeatedly over 3 weeks. After a 2-week rest, a single patch was applied again to the induction site and to a new, untreated site for the challenge phase. Clinical trial: monocentric blind study of GGO (0.01% weight) versus placebo on a multi-ethnic panel with pigmentation spots.Results Safety: No skin irritation or adverse effects were observed in the patch test assay confirming the product's excellent safety. On the 100 volunteers, during the induction period, no reaction of irritation was observed after 3 weeks and during the challenge phase, no allergic reaction was observed. Based on these results, GGO demonstrated very good skin compatibility and does not show a sensitizing effect. Efficacy: all subgroups showed significant depigmentation from Day 21 onwards, which continued to increase in a similar manner to that observed with localized depigmentation. After 84 days, the level of depigmentation achieved was 10% on Asian, 14% on Caucasian and North African skin, and 24% on black skin. Dark Pigmentation spots on Asian and Caucasian skin depigmented at a rate 34% faster than the overall skin tone, resulting in their visual fadingConclusion Glucuronyl Glucosyloleanolate, identified through AI-enhanced biopharma strategies, shows strong skin-brightening efficacy and safety. It depigments dark spots faster than skin tone brightening in an 84-day clinical trial. Non-irritant and potent at low doses, it promises broad cosmetic and medical applications (melasma). Future investigations should assess its anti-aging and antioxidative potential to broaden its scope of application.
BACKGROUND:Nasolabial folds (NLFs) are common age-related facial lines, often treated with dermal fillers. Princess FILLER Lidocaine (PFL; now saypha filler Lidocaine) and Juvéderm Ultra XC (JUXC) are both hyaluronic acid-based fillers used for this purpose. OBJECTIVES:The aim of the authors of this study is to evaluate the effectiveness and safety of PFL in reducing NLF severity compared with JUXC using a split-face study design. METHODS:In this randomized, subject- and investigator-blinded multicenter study, patients with moderate-to-severe NLFs received PFL on one side of the face and JUXC on the other. Baseline NLF severity was assessed using the 5-point NLF-Severity Rating Scale (NLF-SRS). Follow-up assessments occurred at Weeks 12, 24, 36, and/or 48. The primary endpoint was the proportion of NLF-SRS responders at Week 24. Secondary endpoints included assessments by photographic reviewers and treating investigators, along with Global Aesthetic Improvement Scale (GAIS) ratings. Safety was monitored by adverse event reporting and patient diaries. FACE-Q questionnaires evaluated patient satisfaction. Repeat treatment was permitted at Week 36 or 48 if needed. RESULTS:At Week 24, PFL demonstrated noninferiority to JUXC (82.2% vs 81.9% responders; difference 0.37%, P < .0001). Secondary assessments confirmed this finding. Adverse events occurred in 24.4% of patients post PFL, with most being mild to moderate. Serious treatment-emergent adverse events were rare (1.1%). CONCLUSIONS:PFL is a noninferior alternative to JUXC for treating moderate-to-severe NLFs, with comparable efficacy, safety, and patient satisfaction. LEVEL OF EVIDENCE: 1 (THERAPEUTIC):For image description, please refer to the figure legend and surrounding text.
Autologous platelet-rich plasma (PRP) is widely used for alopecia, but outcomes are often inconsistent due to procedural differences and patient-to-patient biological variability, including platelet yield, leukocyte content, and the mixed presence of stimulatory and inhibitory mediators. This commentary outlines a rationale for moving from variable autologous PRP toward defined PRP-inspired, growth-factor-based platelet mimetic formulations with batch-specified concentrations and relative proportions to enable more reproducible dosing and clearer clinical evaluation, aligned with Precision Re-Engineered Efficacy Optimization as a framework for standardizing potency, composition, and performance. Such formulations may improve consistency and scalability, but should be viewed as controlled reconstructions of selected PRP-associated signals rather than complete replicas of platelet releasate. Their translational value will depend on careful formulation characterization, staged proof-of-concept testing, and controlled clinical studies to establish safety, dosing, and comparative effectiveness.
BACKGROUND:Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit and one of the most prevalent dermatological conditions globally. Its multifactorial pathogenesis and variable clinical presentation necessitate a multimodal therapeutic approach. While pharmacological interventions remain first-line therapy, cosmetic and dermatologic procedures are increasingly utilized as adjunctive strategies to enhance clinical outcomes. This narrative review synthesizes current evidence on four commonly employed cosmetic modalities in acne management: chemical peels, mechanical peels, light-based therapies, and radiofrequency-assisted microneedling. AIM:The aim of this study is to evaluate the role of procedural treatments as adjunctive options in the management of acne vulgaris. METHODS:A literature search was performed in PubMed, Web of Science, and Scopus with no time restrictions, focusing on patients with acne vulgaris and adjunct cosmetic/procedural interventions. RESULTS:Given the narrative scope, this was a non-comprehensive, non-exhaustive evidence synthesis, with treatment options organized thematically. Overall, these cosmetic procedures can provide meaningful adjunctive benefits when integrated into individualized acne treatment plans. However, variability in study designs, procedural parameters, and outcome measures limits direct comparison across modalities. Further high-quality randomized controlled trials are necessary to establish standardized protocols and to determine long-term safety and efficacy. CONCLUSIONS:Procedural treatments can serve as valuable adjuncts in the management of acne vulgaris by enhancing therapeutic outcomes and addressing treatment-resistant cases. However, individualized treatment selection and further high-quality studies are needed to optimize their use and long-term benefits.